Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vesiderm is a Singapore-based biotechnology company specializing in advanced liposome-based delivery systems for skincare and therapeutic applications. Spun off from the Agency for Science, Technology and Research (A*STAR) and the National University of Singapore (NUS), the company utilizes proprietary liposome technology to stabilize and deliver active ingredients, such as ceramides, deep into the skin barrier. Their primary focus is on addressing inflammatory skin conditions like eczema and atopic dermatitis through both consumer dermo-cosmetic products and clinical-grade formulations. Vesiderm's platform enhances the bioavailability and efficacy of topical treatments, providing long-lasting hydration and barrier repair. The company's research-driven approach aims to bridge the gap between traditional skincare and pharmaceutical dermatology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vesiderm.